Dewpoint Therapeutics Launches with $60 Million Series A to Advance Proprietary Platform for Drugging Condensates

January 30th, 2019 | Dewpoint

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A. Founding investor Polaris Partners led the equity round and was joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer.

Full article